Most Recent
Australia's richest person Gina Rinehart could be on the hook for millions of dollars in royalty payments, in a long-running battle over lucrative iron ore mining tenements in Western Australia's Pilbara region.
Construction PRO
Mining magnate Gina Rinehart is on the hook for royalties payable to the heirs of iron ore pioneers Don Rhodes and Peter Wright, a judge has held in a long-running battle over lucrative tenements in the Pilbara region.
US-based drug maker Cosette has lost its bid to stay proceedings alleging it induced the treasurer to reject its $672 million tie-up with Mayne Pharma, with a judge finding Mayne has a right to prosecute its case and would be prejudiced by the delay.
A judge has refused to disqualify himself from case managing Mayne Pharma's latest dispute with US drug maker Cosette over the collapse of their $672 million merger agreement, calling the bid “plainly premature”.
Mayne Pharma has launched a bid for a $13.6 million gross sum costs order against US drug maker Cosette, after winning one of numerous legal challenges over the termination of a $672 million merger agreement.
Crown Resorts has lost a fight against a proposal by funders for iProsperity Group's liquidators to put up an after-the-event insurance policy as security for costs in a case that seeks to recover $55 million in gambling losses.
The privacy watchdog has given a preliminary view that it won't investigate a class action-style complaint brought by Maurice Blackburn over a 2022 Optus data breach, citing its own proceedings, a court has heard.
A judge has stayed a bid by the Illawarra Hawks and Melbourne Phoenix basketball clubs for preliminary discovery to determine whether to pursue claims against the National Basketball League.
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.